Which has stronger valuation and earnings, ZURA or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is ZURA or GHRS more profitable?

GH Research's return on equity of -19.36% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% GH Research N/A -19.36% -18.73%

Which has higher earnings and valuation, AAPG or ZURA?

Zura Bio has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 21.04 -$177.71M N/A N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is AAPG or ZURA more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Zura Bio N/A -55.74% -48.07%

Does the media prefer AAPG or ZURA?

In the previous week, Ascentage Pharma Group International had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of -0.11 beat Ascentage Pharma Group International's score of -0.35 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HROW or ZURA?

Harrow has higher revenue and earnings than Zura Bio. Harrow is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.85 -$5.14M -$0.41 N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is HROW or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Zura Bio N/A -55.74% -48.07%

Does the media prefer HROW or ZURA?

In the previous week, Harrow and Harrow both had 2 articles in the media. Harrow's average media sentiment score of 0.00 beat Zura Bio's score of -0.11 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, AVBP or ZURA?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is AVBP or ZURA more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Zura Bio N/A -55.74% -48.07%

Does the media favor AVBP or ZURA?

In the previous week, Zura Bio had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.92 beat Zura Bio's score of -0.11 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ZURA or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ZURA or MLTX more profitable?

Zura Bio's return on equity of -55.74% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to ZURA or MLTX?

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Zura Bio. MoonLake Immunotherapeutics' average media sentiment score of 0.47 beat Zura Bio's score of -0.11 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zura Bio (ZURA) Competitors

$5.17 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.25 +0.08 (+1.47%)

As of 07/2/2026 07:46 PM Eastern

Compare

ZURA vs. GHRS, AAPG, HROW, AVBP, and MLTX

Should you buy Zura Bio stock or one of its competitors? MarketBeat compares Zura Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zura Bio include GH Research (GHRS), Ascentage Pharma Group International (AAPG), Harrow (HROW), ArriVent BioPharma (AVBP), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Zura Bio compare to GH Research?

Zura Bio (NASDAQ:ZURA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Zura Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, GH Research has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Zura Bio currently has a consensus price target of $10.75, suggesting a potential upside of 107.93%. GH Research has a consensus price target of $40.38, suggesting a potential upside of 49.48%. Given Zura Bio's higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Zura Bio had 2 more articles in the media than GH Research. MarketBeat recorded 2 mentions for Zura Bio and 0 mentions for GH Research. GH Research's average media sentiment score of 0.00 beat Zura Bio's score of -0.11 indicating that GH Research is being referred to more favorably in the news media.

Company	Overall Sentiment
Zura Bio	Neutral
GH Research	Neutral

GH Research's return on equity of -19.36% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
GH Research	N/A	-19.36%	-18.73%

GH Research is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Summary

GH Research beats Zura Bio on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Ascentage Pharma Group International had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of -0.11 beat Ascentage Pharma Group International's score of -0.35 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	21.04	-$177.71M	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Ascentage Pharma Group International's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Zura Bio	N/A	-55.74%	-48.07%

61.1% of Zura Bio shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Ascentage Pharma Group International currently has a consensus target price of $46.43, suggesting a potential upside of 150.97%. Zura Bio has a consensus target price of $10.75, suggesting a potential upside of 107.93%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Ascentage Pharma Group International beats Zura Bio on 9 of the 13 factors compared between the two stocks.

How does Zura Bio compare to Harrow?

Harrow (NASDAQ:HROW) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Harrow has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Harrow has higher revenue and earnings than Zura Bio. Harrow is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.85	-$5.14M	-$0.41	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

72.8% of Harrow shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Harrow and Harrow both had 2 articles in the media. Harrow's average media sentiment score of 0.00 beat Zura Bio's score of -0.11 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Zura Bio	N/A	-55.74%	-48.07%

Harrow presently has a consensus price target of $69.43, suggesting a potential upside of 62.44%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 107.93%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Harrow beats Zura Bio on 10 of the 15 factors compared between the two stocks.

How does Zura Bio compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

ArriVent BioPharma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

In the previous week, Zura Bio had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.92 beat Zura Bio's score of -0.11 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma presently has a consensus price target of $43.14, indicating a potential upside of 24.44%. Zura Bio has a consensus price target of $10.75, indicating a potential upside of 107.93%. Given Zura Bio's higher probable upside, analysts plainly believe Zura Bio is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

ArriVent BioPharma's return on equity of -48.98% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Zura Bio	N/A	-55.74%	-48.07%

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zura Bio beats ArriVent BioPharma on 7 of the 13 factors compared between the two stocks.

How does Zura Bio compare to MoonLake Immunotherapeutics?

Zura Bio (NASDAQ:ZURA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zura Bio currently has a consensus target price of $10.75, indicating a potential upside of 107.93%. MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.78%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Zura Bio has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Zura Bio. MoonLake Immunotherapeutics' average media sentiment score of 0.47 beat Zura Bio's score of -0.11 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Zura Bio's return on equity of -55.74% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Summary

Zura Bio beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$490.53M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-4.74	21.61	28.02	24.70
Price / Sales	N/A	343.35	538.99	99.06
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	3.75	8.66	10.96	6.46
Net Income	-$99.35M	$23.81M	$3.57B	$337.01M
7 Day Performance	-3.36%	3.39%	2.12%	1.69%
1 Month Performance	52.06%	10.81%	5.25%	3.81%
1 Year Performance	355.11%	62.61%	33.29%	23.90%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.9555 of 5 stars	$5.17 flat	$10.75 +107.9%	+355.1%	$490.53M	N/A	N/A	3	Analyst Forecast
GHRS GH Research	3.0546 of 5 stars	$23.61 +6.9%	$40.38 +71.0%	+81.2%	$1.62B	N/A	N/A	10	Gap Down
AAPG Ascentage Pharma Group International	4.5295 of 5 stars	$17.08 -0.3%	$46.43 +171.8%	-56.8%	$1.60B	$82.10M	N/A	600	News Coverage High Trading Volume
HROW Harrow	3.9175 of 5 stars	$42.78 +0.9%	$69.43 +62.3%	+34.5%	$1.59B	$268.68M	N/A	180
AVBP ArriVent BioPharma	2.3278 of 5 stars	$33.74 +3.2%	$43.38 +28.6%	+67.0%	$1.57B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. GHRS, AAPG, HROW, AVBP, and MLTX

How does Zura Bio compare to GH Research?

Summary

How does Zura Bio compare to Ascentage Pharma Group International?

Summary

How does Zura Bio compare to Harrow?

Summary

How does Zura Bio compare to ArriVent BioPharma?

Summary

How does Zura Bio compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. GHRS, AAPG, HROW, AVBP, and MLTX

How does Zura Bio compare to GH Research?

Which has more volatility and risk, ZURA or GHRS?

Do analysts recommend ZURA or GHRS?

Do institutionals and insiders hold more shares of ZURA or GHRS?

Does the media refer more to ZURA or GHRS?

Is ZURA or GHRS more profitable?

Which has stronger valuation and earnings, ZURA or GHRS?

Summary

How does Zura Bio compare to Ascentage Pharma Group International?

Does the media prefer AAPG or ZURA?

Which has higher earnings and valuation, AAPG or ZURA?

Is AAPG or ZURA more profitable?

Do institutionals & insiders hold more shares of AAPG or ZURA?

Which has more risk and volatility, AAPG or ZURA?

Do analysts rate AAPG or ZURA?

Summary

How does Zura Bio compare to Harrow?

Which has more volatility and risk, HROW or ZURA?

Which has preferable earnings & valuation, HROW or ZURA?

Do insiders & institutionals hold more shares of HROW or ZURA?

Does the media prefer HROW or ZURA?

Is HROW or ZURA more profitable?

Do analysts rate HROW or ZURA?

Summary

How does Zura Bio compare to ArriVent BioPharma?

Which has stronger valuation & earnings, AVBP or ZURA?

Which has more risk and volatility, AVBP or ZURA?

Does the media favor AVBP or ZURA?

Do analysts prefer AVBP or ZURA?

Is AVBP or ZURA more profitable?

Do institutionals and insiders have more ownership in AVBP or ZURA?

Summary

How does Zura Bio compare to MoonLake Immunotherapeutics?

Do insiders & institutionals have more ownership in ZURA or MLTX?

Do analysts prefer ZURA or MLTX?

Which has more volatility & risk, ZURA or MLTX?

Does the media refer more to ZURA or MLTX?

Which has preferable valuation and earnings, ZURA or MLTX?

Is ZURA or MLTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools